Lupin, Biocon, Dr Reddy Share Price Jump as Nifty Pharma Rallies 3% on US–India Trade Deal

Pharmaceutical stocks surged on Tuesday, February 3, after the US and India reached a trade deal that lowered tariffs on Indian exports to 18% from the earlier 50%. The move lifted sentiment across pharma counters.
At around 9:30 am, the Nifty Pharma index was up nearly 3%, outperforming the broader market. In comparison, the Nifty 50 was trading about 2.7% higher.
Lupin, Biocon, Dr Reddy’s Lead Gains
Several pharma stocks saw strong buying interest. Aurobindo Pharma and Wockhardt jumped nearly 5%. Dr Reddy’s, Sun Pharma, Divi’s Laboratories, Piramal Pharma and Mankind Pharma gained over 3%.
Stocks such as Lupin, Biocon, Glenmark Pharma, Zydus Lifesciences and Alkem Laboratories were also up more than 2%.
Also Read: Best Long-Term Stocks in Jan 2026 – 5yr CAGR Basis!
Conclusion
The sharp rally in pharma stocks reflects optimism around improved margins and earnings after the US–India trade deal. With lower tariffs easing export pressures, US-focused pharma companies are likely to remain in focus in the near term.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 3, 2026, 11:06 AM IST

Kusum Kumari
- Allied Blenders and Distillers Share Price in Focus; Records Highest-Ever Monthly Sales in September and October
- Lenskart Solutions Share Price in Focus; Q2FY27 Profit More Than Doubles as Revenue Rises 36%
- Keystone Realtors Share Price in Focus; Reports 84% Rise in Pre-Sales in Q2 FY27
- Parag Milk Foods Share Price Surges Over 17% After Q2 FY27 Earnings Results; Revenue Hits Record ₹1,241 Crore
- BASF India Share Price in Focus; Net Profit Declines 42.4% in Q2FY27




